Webdisclosure.com

POLYPHOR AG

08/02/2023 07:20

Spexis and SPRIM Global Investments (SGI) Announce Plans for Clinical Trial Partnership to Fund up to Half of the Projected Phase 3 Clinical Development Costs of ColiFin®

Voir tous les communiqués de Polyphor AG

POLYPHOR AG

25/01/2023 12:56

Original-Research: Spexis AG (von First Berlin Equity Research GmbH): Buy

Voir tous les communiqués de Polyphor AG

POLYPHOR AG

09/01/2023 07:15

Spexis reports solid safety and pharmacokinetics results from first-in-human study with inhaled murepavadin, a novel macrocycle compound

Voir tous les communiqués de Polyphor AG

POLYPHOR AG

13/12/2022 07:30

Spexis announces promising pre-clinical data with balixafortide in combination with various therapies on the market for treating B-cell lymphomas

Voir tous les communiqués de Polyphor AG

POLYPHOR AG

18/10/2022 07:30

Spexis to present at BIO-Europe® 2022

Voir tous les communiqués de Polyphor AG

POLYPHOR AG

22/09/2022 07:15

Spexis announces positive renal impairment clinical trial results with balixafortide

Voir tous les communiqués de Polyphor AG

POLYPHOR AG

06/09/2022 07:15

Spexis provides business update and announces financial results for the first half of 2022

Voir tous les communiqués de Polyphor AG

POLYPHOR AG

31/08/2022 07:30

Spexis announces presentation of half-year 2022 financial results and participation at upcoming industry and investor events in September

Voir tous les communiqués de Polyphor AG

POLYPHOR AG

28/07/2022 07:15

Spexis provides business update

Voir tous les communiqués de Polyphor AG

POLYPHOR AG

25/07/2022 19:25

Spexis announces business update call to be held on July 28th

Voir tous les communiqués de Polyphor AG

1
2
3
4
5
6
7
8
9
10